Anti-c5 agent for treatment of dry age-related macular degeneration (amd) or geographic atrophy secondary to dry amd

A method for treating a subject with geographic atrophy secondary to dry age-related macular degeneration, the method comprising administering to the subject an anti-C5 agent,

• wherein the anti-C5 agent comprises a C5-specific aptamer comprising the following structure:
• or a salt thereof,
• wherein Aptamer=fCmGfCfCGfCmGmGfUfCfUfCmAmGmGfCGfCfUmGmAmGfUfCfUmGmAmGfUfU fUAfCfCfUmGfCmG-3T (SEQ ID NO:
• 1), wherein fC and fU=2′ fluoronucleotides, mG and mA=2′-OMe nucleotides, all other nucleotides are 2′-OH, and 3T indicates an inverted deoxythymidine;
• wherein the anti-C5 agent is administered to the subject in a loading phase followed by a maintenance phase, wherein the loading phase comprises administering the anti-C5 agent at a dose of about 2 mg/eye for a duration of twelve months at a frequency in which the duration between doses is one month, and wherein the maintenance phase comprises administering the anti-C5 agent at a dose of about 2 mg/eye thereafter at a frequency in which the duration between doses is two months;
• and
• wherein the anti-C5 agent is administered intraocularly to the subject via intravitreal injection into the eye.